

April 6, 2024

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir

Reg: Disclosure under Regulation 30 of SEBI Listing Regulations

Sub: Completion of US-FDA Inspection at the Formulations Facility of Strides Alathur Private Limited, a wholly owned subsidiary of the Company

We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Formulations Facility of Strides Alathur Private Limited, a wholly owned subsidiary of the Company, at Alathur, Chennai during the week of April 1, 2024 to April 5, 2024.

The inspection closed with two observations. Company will respond to these observations comprehensively to FDA within the stipulated time.

We will keep the stock exchanges informed if there is any further update in this matter.

Please take the above information on record.

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515